Sanofi Acquires Blueprint in $9.1B Deal to Bolster Rare Immunological Disease Pipeline
Sanofi has announced a definitive agreement to acquire Blueprint Medicines, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and
Read more